Our management team of highly qualified executives includes its Key Persons and a medical science Board of Advisors with deep experience in clinical medicine, the science of Precision Medicine, and Management of Organizations.
Don Cooper, President and Chief Executive Officer (CEO), is a former staff member for the Chairman of the Science and Technology Committee of the U.S. House of Representatives, a securities trader, and a former Northern Virginia area real estate developer. He has held C-level positions in hospitality, information technology (IT), and communications start-ups with the most recent being, Regenera, LLC, a stem cell company he founded with Dr. Yves Gerard Illouz of Paris, creator of liposuction.
Fernando Vidal-Vanaclocha, MD/PhD, Chief Science Officer (CSO), is a physician scientist, trained in Pathology, and a professor of Translational Molecular Medicine. He has extensive experience in discovery and translational research in Oncology, Inflammation, and Regenerative Medicine. He has been very interested in moving laboratory discoveries to applications and has founded several biotech entities in Spain (INBIOMED, PHARMAKINE, IMMA) and in the U.S. (BIOPHARMANCE and more recently, Persona Biomed), all of which are focused on the development and commercialization of products and services for molecular diagnosis and target-oriented therapeutics. Currently, he is also a research professor at the Department of Biochemistry and Molecular Medicine at George Washington University School of Medicine, Washington, D.C.
Michael Coury, Director of Marketing and Sales of Pharmaceutical Laboratory Services, has spent 12 years at Thermo Fisher Scientific as a critical member of the senior staff who successfully performed in the following positions: Senior Clinical Oncology Sales Specialist for the Mid-Atlantic region, Corporate Accounts Executive at NIH, District Sales Manager for the Mid-Atlantic Region, and Genetic Solutions. Thermo Fisher Scientific is a $35 billion, 90,000 employee company with unique laboratory platforms and technologies which improves patient outcomes and treatments. In his earlier nine years, he was the Instrument Sales Specialist at QIAGEN and the System Biology Sales Consultant for Beckman Coulter.